Published in J Clin Invest on February 01, 1983
Infectious diseases associated with complement deficiencies. Clin Microbiol Rev (1991) 4.01
Constitutive versus activation-dependent cross-presentation of immune complexes by CD8(+) and CD8(-) dendritic cells in vivo. J Exp Med (2002) 2.32
Human C3b/C4b receptor (CR1). Demonstration of long homologous repeating domains that are composed of the short consensus repeats characteristics of C3/C4 binding proteins. J Exp Med (1987) 2.28
Neutrophil and monocyte cell surface p150,95 has iC3b-receptor (CR4) activity resembling CR3. J Clin Invest (1988) 1.92
Pathogenesis and pathophysiology of pneumococcal meningitis. Clin Microbiol Rev (2011) 1.87
Blockade of clearance of immune complexes by an anti-Fc gamma receptor monoclonal antibody. J Exp Med (1986) 1.75
The effect of antibody isotype and antigenic epitope density on the complement-fixing activity of immune complexes: a systematic study using chimaeric anti-NIP antibodies with human Fc regions. Clin Exp Immunol (1991) 1.68
Identification of a restriction fragment length polymorphism by a CR1 cDNA that correlates with the number of CR1 on erythrocytes. J Exp Med (1986) 1.56
Human erythrocytes bind and inactivate type 5 adenovirus by presenting Coxsackie virus-adenovirus receptor and complement receptor 1. Blood (2009) 1.51
Complement-mediated tumor cell damage induced by antibodies against membrane cofactor protein (MCP, CD46). J Exp Med (1990) 1.49
Complement depletion accelerates the clearance of immune complexes from the circulation of primates. J Clin Invest (1984) 1.46
Altered erythrocyte C3b receptor expression, immune complexes, and complement activation in homosexual men in varying risk groups for acquired immune deficiency syndrome. J Clin Invest (1986) 1.40
Association between C4, C4A, and C4B copy number variations and susceptibility to autoimmune diseases: a meta-analysis. Sci Rep (2017) 1.39
Drug delivery by red blood cells: vascular carriers designed by mother nature. Expert Opin Drug Deliv (2010) 1.30
The role of hypocomplementaemia and low erythrocyte complement receptor type 1 numbers in determining abnormal immune complex clearance in humans. Clin Exp Immunol (1989) 1.24
Ligation of Fc gamma receptor IIB inhibits antibody-dependent enhancement of dengue virus infection. Proc Natl Acad Sci U S A (2011) 1.24
Control of the function of substrate-bound C4b-C3b by the complement receptor Cr1. J Exp Med (1984) 1.23
Immune complex processing in patients with systemic lupus erythematosus. In vivo imaging and clearance studies. J Clin Invest (1992) 1.23
Meningococcal disease and the complement system. Virulence (2013) 1.19
Mapping of the C3b-binding site of CR1 and construction of a (CR1)2-F(ab')2 chimeric complement inhibitor. J Exp Med (1991) 1.18
PspA and PspC minimize immune adherence and transfer of pneumococci from erythrocytes to macrophages through their effects on complement activation. Infect Immun (2007) 1.17
Loss of complement receptor type 1 (CR1) on ageing of erythrocytes. Studies of proteolytic release of the receptor. Biochem J (1986) 1.16
Structure of the human CR1 gene. Molecular basis of the structural and quantitative polymorphisms and identification of a new CR1-like allele. J Exp Med (1989) 1.15
Clearance of soluble aggregates of human immunoglobulin G in healthy volunteers and chimpanzees. Clin Exp Immunol (1987) 1.12
Mapping epitopes for 20 monoclonal antibodies to CR1. Clin Exp Immunol (1998) 1.12
Differential binding of immunoglobulin A and immunoglobulin G1 immune complexes to primate erythrocytes in vivo. Immunoglobulin A immune complexes bind less well to erythrocytes and are preferentially deposited in glomeruli. J Clin Invest (1986) 1.11
Decreased C3b receptors (CR1) on erythrocytes from patients with systemic lupus erythematosus. Clin Exp Immunol (1986) 1.09
Great genotypic and phenotypic diversities associated with copy-number variations of complement C4 and RP-C4-CYP21-TNX (RCCX) modules: a comparison of Asian-Indian and European American populations. Mol Immunol (2009) 1.07
Immune complexes and erythrocyte CR1 (complement receptor type 1): effect of CR1 numbers on binding and release reactions. Clin Exp Immunol (1988) 1.06
Family study of the major histocompatibility complex in HLA DR3 negative patients with systemic lupus erythematosus. Clin Exp Immunol (1987) 1.05
Hepatic uptake of circulating IgG immune complexes. Immunology (1985) 1.05
Phenotypes, genotypes and disease susceptibility associated with gene copy number variations: complement C4 CNVs in European American healthy subjects and those with systemic lupus erythematosus. Cytogenet Genome Res (2009) 1.03
Tetanus toxoid-anti-tetanus toxoid complexes: a potential model to study the complement transport system for immune complex in humans. Clin Exp Immunol (1987) 1.02
Erythrocytes transfused into patients with SLE and haemolytic anaemia lose complement receptor type 1 from their cell surface. Clin Exp Immunol (1987) 1.01
Stealth properties to improve therapeutic efficacy of drug nanocarriers. J Drug Deliv (2013) 0.99
A transgenic mouse model for studying the clearance of blood-borne pathogens via human complement receptor 1 (CR1). Clin Exp Immunol (2005) 0.99
Autoantibody to the C3b/C4b receptor and absence of this receptor from erythrocytes of a patient with systemic lupus erythematosus. J Clin Invest (1985) 0.98
C1q receptors. Clin Exp Immunol (2000) 0.98
In vivo handling of soluble complement fixing Ab/dsDNA immune complexes in chimpanzees. J Clin Invest (1989) 0.97
Manipulation of lymphoid microenvironments in nonhuman primates by an inhibitor of the lymphotoxin pathway. J Clin Invest (2002) 0.97
The polymorphism of the C3b/C4b receptor in the normal population and in patients with systemic lupus erythematosus. Clin Exp Immunol (1987) 0.96
Predominance of HA-222D/G polymorphism in influenza A(H1N1)pdm09 viruses associated with fatal and severe outcomes recently circulating in Germany. PLoS One (2013) 0.95
Abnormal clearance of soluble aggregates of human immunoglobulin G in patients with systemic lupus erythematosus. Clin Exp Immunol (1988) 0.95
Comparative functional evolution of human and mouse CR1 and CR2. J Immunol (2008) 0.95
Expression and localization of proteins of the complement system in human skin. J Clin Invest (1992) 0.94
Ligation of erythrocyte CR1 induces its clustering in complex with scaffolding protein FAP-1. Blood (2008) 0.94
Complement receptor expression and activation of the complement cascade on B lymphocytes from patients with systemic lupus erythematosus (SLE). Clin Exp Immunol (1995) 0.94
Reduced immune complex binding capacity and increased complement susceptibility of red cells from children with severe malaria-associated anemia. Mol Med (2008) 0.93
Mechanism of transfer of immune complexes from red blood cell CR1 to monocytes. Clin Exp Immunol (1992) 0.92
Quantitative variations of the C3b/C4b receptor (CR1) in human erythrocytes are controlled by genes within the regulator of complement activation (RCA) gene cluster. J Exp Med (1986) 0.92
Dynamics of interaction between complement-fixing antibody/dsDNA immune complexes and erythrocytes. In vitro studies and potential general applications to clinical immune complex testing. J Clin Invest (1985) 0.92
Consumption of erythrocyte CR1 (CD35) is associated with protection against systemic lupus erythematosus renal flare. Clin Exp Immunol (2006) 0.92
The rate of loss of CR1 from ageing erythrocytes in vivo in normal subjects and SLE patients: no correlation with structural or numerical polymorphisms. Clin Exp Immunol (1988) 0.92
Immune complex processing in C1q-deficient mice. Clin Exp Immunol (2001) 0.90
Immune complex binding efficiency of erythrocyte complement receptor 1 (CR1). Clin Exp Immunol (1991) 0.89
Human umbilical vein endothelial cells express complement receptor 1 (CD35) and complement receptor 4 (CD11c/CD18) in vitro. Inflammation (2002) 0.87
Blood clearance and tissue localization of soluble aggregates of IgG in NZB/W and NZB mice. Immunology (1985) 0.86
The binding of immune complexes to human red cells: complement requirements and fate of the RBC-bound IC after interaction with human phagocytic cells. Clin Exp Immunol (1986) 0.85
Erythrocyte complement receptor type 1 (CR1) expression and circulating immune complex (CIC) levels in hydralazine-induced SLE. Clin Exp Immunol (1987) 0.85
Use of heteropolymeric monoclonal antibodies to attach antigens to the C3b receptor of human erythrocytes: a potential therapeutic treatment. Proc Natl Acad Sci U S A (1991) 0.84
Antibody buffering of a ligand in vivo. Proc Natl Acad Sci U S A (2004) 0.84
BSA-anti-BSA immune complexes formed in the presence of human complement do not bind to autologous red blood cells. Immunology (1988) 0.84
Regulation of circulating immune complexes by complement receptor type 1 on erythrocytes in chronic viral liver diseases. Gut (2002) 0.83
Chronic serum sickness glomerulonephritis: removal of glomerular antigen and electron-dense deposits is largely dependent on plasma complement. Clin Exp Immunol (1988) 0.83
Human mononuclear phagocyte molecules and the use of monoclonal antibodies in their detection. Clin Exp Immunol (1987) 0.82
Genetics of sarcoidosis: candidate genes and genome scans. Proc Am Thorac Soc (2007) 0.82
Evaluation of in vivo immune complex formation and complement activation in patients receiving intravenous streptokinase. Clin Exp Immunol (1993) 0.82
C3b receptor (CR1) expression on the polymorphonuclear leukocytes from patients with systemic lupus erythematosus. Clin Exp Immunol (1987) 0.82
Immune adherence and clearance of hepatitis B surface Ag/Ab complexes is abnormal in patients with systemic lupus erythematosus (SLE). Clin Exp Immunol (1991) 0.81
Increased frequency of the long (S) allotype of CR1 (the C3b/C4b receptor, CD35) in patients with systemic lupus erythematosus. Clin Exp Immunol (1992) 0.81
Elimination of soluble 123I-labelled aggregates of human immunoglobulin G in humans; the effect of splenectomy. Clin Exp Immunol (1989) 0.81
Subcapsular sinus macrophages limit acute gammaherpesvirus dissemination. J Gen Virol (2015) 0.81
Quantitative analysis of C4Ab and C4Bb binding to the C3b/C4b receptor (CR1, CD35). Clin Exp Immunol (1997) 0.80
Opsonized streptococcal cell walls cross-link human leukocytes and erythrocytes by complement receptors. Infect Immun (1985) 0.80
Peripheral catabolism of CR1 (the C3b receptor, CD35) on erythrocytes from healthy individuals and patients with systemic lupus erythematosus (SLE). Clin Exp Immunol (1992) 0.80
CR1 deficiency in SLE: acquired or genetic? Clin Exp Immunol (1985) 0.80
A lysine-binding protein in SLE sera inhibits the binding of immune complexes to normal erythrocyte CR1 (complement receptor type 1). Clin Exp Immunol (1987) 0.80
Complement-independent binding of microorganisms to primate erythrocytes in vitro by cross-linked monoclonal antibodies via complement receptor 1. Infect Immun (1995) 0.80
First clinical trials of a new heteropolymer technology agent in normal healthy volunteers and patients with systemic lupus erythematosus: safety and proof of principle of the antigen-heteropolymer ETI-104. Ann Rheum Dis (2004) 0.80
Fc receptor function and circulating immune complexes in gluten sensitive enteropathy--possible significance of serum IgA. Gut (1991) 0.79
Deficiency of complement component C3 is associated with accelerated removal of soluble 123I-labelled aggregates of IgG from the circulation. Clin Exp Immunol (1992) 0.79
Immune adherence of nascent hepatitis B surface antigen-antibody complexes in vivo in humans. Clin Exp Immunol (1989) 0.79
CR1 polymorphism in hydralazine-induced systemic lupus erythematosus: DNA restriction fragment length polymorphism. Clin Exp Immunol (1989) 0.79
MRL-lpr/lpr mice show an impairment of IgG aggregate removal which relates to parameters of disease activity. Immunology (1987) 0.79
An assessment of the influence of antigen dose in two new models of chronic serum sickness glomerulonephritis in the rat. Br J Exp Pathol (1987) 0.78
C3b receptor (CR1) on phagocytic cells from SLE patients: analysis of the defect and familial study. Clin Exp Immunol (1988) 0.78
Erythrocytes from young but not elderly donors can bind and degrade immune complex- and antibody-bound C3 in vitro. Clin Exp Immunol (1994) 0.78
The change in C3b receptors on erythrocytes from patients with systemic lupus erythematosus. Clin Exp Immunol (1985) 0.78
Exposure to complement-bearing immune complexes enhances the in vitro sequestration of erythrocytes from young but not elderly donors. Clin Exp Immunol (1993) 0.78
Development of complement therapeutics for inhibition of immune-mediated red cell destruction. Transfusion (2005) 0.78
Neisseria meningitidis and Escherichia coli are protected from leukocyte phagocytosis by binding to erythrocyte complement receptor 1 in human blood. Mol Immunol (2011) 0.78
Clonal variations in complement activation and deposition of C3b and C4b on model immune complexes. Immunology (1993) 0.78
Gene CNVs and protein levels of complement C4A and C4B as novel biomarkers for partial disease remissions in new-onset type 1 diabetes patients. Pediatr Diabetes (2011) 0.78
Altered distribution of intraglomerular immune complexes in C3-deficient mice. Immunology (1999) 0.77
Proteomic Insight Reveals Elevated Levels of Albumin in Circulating Immune Complexes in Diabetic Plasma. Mol Cell Proteomics (2016) 0.77
Complement-component-C3-opsonized immunoglobulin G anti-DNA antibodies do not bind effectively to red blood cells unless aggregated on a high-Mr DNA matrix. Biochem J (1984) 0.77
Complement-regulatory protein expression and activation of complement cascade on erythrocytes from patients with rheumatoid arthritis (RA). Clin Exp Immunol (1998) 0.76
Identification of the membrane glycoprotein that is the C3b receptor of the human erythrocyte, polymorphonuclear leukocyte, B lymphocyte, and monocyte. J Exp Med (1980) 6.49
The role of membrane receptors for C3b and C3d in phagocytosis. J Exp Med (1977) 6.19
Complement receptor (CR1) deficiency in erythrocytes from patients with systemic lupus erythematosus. J Exp Med (1982) 4.96
Detection of antibodies and soluble antigen-antibody complexes by precipitation with polyethylene glycol. J Immunol (1973) 4.28
Studies on circulating immune complexes. 3. Factors governing the ability of circulating complexes to localize in blood vessels. J Exp Med (1968) 3.80
Complement receptor is an inhibitor of the complement cascade. J Exp Med (1981) 3.65
Characteristics of isolated erythrocyte complement receptor type one (CR1, C4b-C3b receptor) and CR1-specific antibodies. J Immunol (1981) 2.74
Defective immune-adherence (C3b) receptor on erythrocytes from patients with systemic lupus erythematosus. Lancet (1981) 2.64
Receptor for albumin on the liver cell surface may mediate uptake of fatty acids and other albumin-bound substances. Science (1981) 2.22
A simple numerical method for the construction of isokinetic sucrose density gradients, and their application to the characterisation of immunoglobulin complexes. J Immunol Methods (1976) 1.95
NIH conference. Pathophysiology of immune hemolytic anemia. Ann Intern Med (1977) 1.79
The red-cell immune system. Lancet (1981) 1.77
Competition for immune complexes by red cells in human blood. J Clin Lab Immunol (1982) 1.74
Studies of reticuloendothelial function in the mouse with model immune complexes. I. Serum clearance and tissue uptake in normal C3H mice. J Immunol (1979) 1.61
The immune adherence receptor: dissociation between the expression of erythrocyte and mononuclear cell C3b receptors. J Immunol (1975) 1.22
Binding of immunoglobulins and immune complexes to erythrocytes of vertebrates. Immunochemistry (1978) 1.14
Ability of complement to release systemic lupus erythematosus immune complexes from cell receptors. Clin Exp Immunol (1981) 1.05
Some hemodynamic determinants of immune complex trapping by the kidney. Kidney Int (1978) 1.05
DNA/anti-DNA complexes: correlation of size and complement fixation. Arthritis Rheum (1981) 1.02
Glomerulonephritis: current problems and understanding. J Lab Clin Med (1982) 0.98
Measurement of the fractional uptake of macromolecules by the renal vascular bed compared to other vascular beds. J Lab Clin Med (1976) 0.97
Detection of circulating immune complexes by using human red blood cells. J Lab Clin Med (1979) 0.93
Interaction of antibody-aggregated C4 and guinea-pig red cells: coagglutination phenomenon of Bordet and Gengou. Immunology (1981) 0.88
Red cell immune adherence (RCIA): its application in cancer and autoimmune disease. Immunol Commun (1981) 0.87
Blood pressure control, proteinuria, and the progression of renal disease. The Modification of Diet in Renal Disease Study. Ann Intern Med (1995) 5.50
Thiazide diuretic monotherapy for hypertension: diuretic's dark side just got darker. Kidney Int (2007) 2.84
Cyclosporine in patients with steroid-resistant membranous nephropathy: a randomized trial. Kidney Int (2001) 2.17
A randomized trial of cyclosporine in patients with steroid-resistant focal segmental glomerulosclerosis. North America Nephrotic Syndrome Study Group. Kidney Int (1999) 1.82
Studies of the mechanism by which phosphate infusion lowers serum calcium concentration. J Clin Invest (1966) 1.81
The living donor in kidney transplantation. Ann Intern Med (1987) 1.81
Interaction of rifampin and glucocorticoids. Adverse effect on renal allograft function. JAMA (1976) 1.77
Serum C3 levels are diagnostically more sensitive and specific for systemic lupus erythematosus activity than are serum C4 levels. The Lupus Nephritis Collaborative Study Group. Am J Kidney Dis (1991) 1.66
Complement depletion accelerates the clearance of immune complexes from the circulation of primates. J Clin Invest (1984) 1.46
Therapy of membranous nephropathy: what to do after the after (meta) analyses. J Am Soc Nephrol (1995) 1.39
Renoprotective therapy: how good can it get? Kidney Int (2000) 1.39
CR1 and CR1-like: the primate immune adherence receptors. Immunol Rev (2001) 1.27
Molecular identification of Knops blood group polymorphisms found in long homologous region D of complement receptor 1. Blood (2001) 1.25
The complex nature of serum C3 and C4 as biomarkers of lupus renal flare. Lupus (2010) 1.21
Spot urine protein/creatinine ratios are unreliable estimates of 24 h proteinuria in most systemic lupus erythematosus nephritis flares. Kidney Int (2007) 1.18
Renal artery dissection causing renal infarction in otherwise healthy men. Am J Kidney Dis (1997) 1.17
Differential binding of immunoglobulin A and immunoglobulin G1 immune complexes to primate erythrocytes in vivo. Immunoglobulin A immune complexes bind less well to erythrocytes and are preferentially deposited in glomeruli. J Clin Invest (1986) 1.11
Pseudomonas septicemia in neutropenic dogs. I. Treatment with granulocyte transfusions. Transfusion (1974) 1.10
5/6 nephrectomy as a validated rat model mimicking human warfarin-related nephropathy. Am J Nephrol (2012) 1.10
The erythrocyte-immune complex-glomerulonephritis connection in man. Kidney Int (1987) 1.07
Some hemodynamic determinants of immune complex trapping by the kidney. Kidney Int (1978) 1.05
Clearance of human antibody/DNA immune complexes and free DNA from the circulation of the nonhuman primate. Clin Immunol Immunopathol (1987) 1.04
Phenotypes, genotypes and disease susceptibility associated with gene copy number variations: complement C4 CNVs in European American healthy subjects and those with systemic lupus erythematosus. Cytogenet Genome Res (2009) 1.03
Complement activation induces the expression of decay-accelerating factor on human mesangial cells. J Immunol (1991) 1.02
Remission of nephrotic syndrome in type 1 diabetes: long-term follow-up of patients in the Captopril Study. Am J Kidney Dis (1999) 1.02
Cytomegalovirus inhibits major histocompatibility class II expression on infected endothelial cells. Am J Pathol (1994) 1.01
The effect of sodium hydroxide and hydrochloric acid on human epidermis. An electronmicroscopic study. Acta Derm Venereol (1972) 1.01
Regulation of paralytic experimental allergic encephalomyelitis in rats: susceptibility to active and passive disease reinduction. J Immunol (1981) 1.00
Identification of the Kna/Knb polymorphism and a method for Knops genotyping. Transfusion (2004) 0.99
Diagnostic significance of hypocomplementemia. Kidney Int (1991) 0.97
Interactions between precipitating and nonprecipitating antibodies in the formation of immune complexes. J Immunol (1987) 0.97
Measurement of the fractional uptake of macromolecules by the renal vascular bed compared to other vascular beds. J Lab Clin Med (1976) 0.97
Evaluation of the mechanisms responsible for the reduction in erythrocyte complement receptors when immune complexes form in vivo in primates. J Immunol (1990) 0.95
The Semmes-Weinstein monofilament as a potential predictor of foot ulceration in patients with noninsulin-dependent diabetes. Am J Med Sci (1995) 0.93
Mycophenolate mofetil therapy in lupus nephritis: clinical observations. J Am Soc Nephrol (1999) 0.93
Consumption of erythrocyte CR1 (CD35) is associated with protection against systemic lupus erythematosus renal flare. Clin Exp Immunol (2006) 0.92
Vitamin D deficiency as marker for disease activity and damage in systemic lupus erythematosus: a comparison with anti-dsDNA and anti-C1q. Lupus (2011) 0.92
Subacute bacterial endocarditis masquerading as type III essential mixed cryoglobulinemia. J Am Soc Nephrol (1997) 0.91
Resection of the internal carotid artery and replacement with greater saphenous vein: a safe procedure for en bloc cancer resections with carotid involvement. J Vasc Surg (1996) 0.91
Modification of the clinical and histopathologic expression of experimental allergic encephalomyelitis by the vasoactive amine antagonist cyproheptadine. Cell Immunol (1984) 0.90
Measurement of SC5b-9 in urine in patients with the nephrotic syndrome. Kidney Int (1991) 0.90
Factors influencing the binding of large immune complexes to the primate erythrocyte CR1 receptor. Clin Immunol Immunopathol (1984) 0.90
Saphenous vein stripping and its complications. Surg Clin North Am (1983) 0.89
Randomized trial of emergency mesocaval and portacaval shunts for bleeding esophageal varices. Am J Surg (1978) 0.89
Progressive myelopathy in older German shepherd dogs. II. Presence of circulating suppressor cells. J Immunol (1980) 0.89
Progressive myelopathy in older German shepherd dogs. I. Depressed response to thymus-dependent mitogens. J Immunol (1980) 0.88
The role of echocardiography in patients with acute peripheral arterial embolization. Ann Vasc Surg (1986) 0.88
Arteriovenous fistulae complicating cardiac pacemaker lead extraction: recognition, evaluation, and management. J Vasc Surg (2000) 0.88
Use of the splenic and hepatic artery for renal revascularization in patients with atherosclerotic renal artery disease. Ann Vasc Surg (1997) 0.86
Distribution and quantitative expression of the complement receptor type 1 (CR1) on human peripheral blood T lymphocytes. Cell Immunol (1992) 0.86
Immune complexes bind preferentially to specific subpopulations of human erythrocytes. Clin Immunol Immunopathol (1990) 0.85
Evidence that abnormally large seasonal declines in vitamin D status may trigger SLE flare in non-African Americans. Lupus (2012) 0.85
Glomerular deposition of immune complexes made with IgG2a monoclonal antibodies. J Immunol (2000) 0.84
Immune complex erythrocyte complement receptor interactions in vivo during induction of glomerulonephritis in nonhuman primates. J Lab Clin Med (1990) 0.84
Hepatorenal and splenorenal artery bypass for salvage of renal function. Ann Vasc Surg (1991) 0.84
Reversal of chronic end-stage renal failure due to myeloma kidney. Ann Intern Med (1979) 0.83
Of mice and men: the relevance of the mouse to the study of human SLE. Immunol Res (2001) 0.83
Rapidly progressive glomerulonephritis superimposed on diabetic glomerulosclerosis. Recognition and treatment. JAMA (1982) 0.82
Renal subcapsular pressure--a new intrarenal pressure measurement. Am J Physiol (1971) 0.82
The chimpanzee and cynomolgus monkey erythrocyte immune adherence receptors are encoded by CR1-like genes. Immunogenetics (2000) 0.82
Radial artery cannulation: a comparison of 15.2- and 4.45-cm catheters. J Clin Monit (1992) 0.82
Lentigo maligna of the fingertip. Clinical, histologic, and ultrastructural studies of two cases. Arch Dermatol (1973) 0.82
The role of the complement system in renal injury. Semin Nephrol (1992) 0.81
Experimental immune complex-mediated glomerulonephritis in the nonhuman primate. Kidney Int (1991) 0.81
The presence of specific antigen-reactive cells during the induction, recovery, and resistance phases of experimental allergic encephalomyelitis. Cell Immunol (1980) 0.81
Biologic significance of the erythrocyte complement receptor: a primate perquisite. J Lab Clin Med (1991) 0.81
Ig N-glycan orientation can influence interactions with the complement system. J Immunol (1997) 0.81
Effect of enalapril therapy on glomerular accumulation of immune complexes and mesangial matrix in experimental glomerulonephritis in the nonhuman primate. Am J Kidney Dis (1997) 0.80
Erythropoietin therapy in humans increases erythrocyte expression of complement receptor type 1 (CD35). J Am Soc Nephrol (1994) 0.80
Antegrade visceral revascularisation via a thoracoabdominal approach for chronic mesenteric ischaemia. Eur J Vasc Endovasc Surg (1999) 0.80
Clinical observations and lessons learned in the treatment of patients with thoracoabdominal aortic aneurysms. Surg Gynecol Obstet (1988) 0.80
Venereal warts vs Bowen disease. A histologic and ultrastructural study of five cases. JAMA (1977) 0.80
Stimulating erythropoiesis increases complement receptor expression on primate erythrocytes. Clin Immunol Immunopathol (1992) 0.80
Pulmonary delivery of nanoparticles of insoluble, iodinated CT X-ray contrast agents to lung draining lymph nodes in dogs. J Pharm Sci (1998) 0.80
Renal artery pressure gradients in patients with angiographic evidence of atherosclerotic renal artery stenosis. Am J Kidney Dis (1994) 0.80
Effect of renal decapsulation on renal function. Am J Physiol (1975) 0.80
Safety of simultaneous aortic reconstruction and renal transplantation. Am J Surg (1991) 0.79
Isolation and characterization of amyloid protein AA in the Abyssinian cat. Lab Invest (1985) 0.79
Stability of renal transplant function with alternate-day corticosteroid therapy. JAMA (1980) 0.79